Genmab A/S (GMAB) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Viatris (VTRS) has outperformed Genmab A/S (GMAB) over the past year, gaining 72.5% versus a gain of 12.3%. Over five years, VTRS leads with a +29.9% price change compared with -17.5% for GMAB. Genmab A/S is the larger company by market cap ($22.17 billion vs $20.03 billion), about 1.1 times the size.
On valuation, Viatris trades at a lower forward P/E (6.5x vs 23.6x for Genmab A/S). Viatris pays a dividend yielding 2.75%, while Genmab A/S does not currently pay one. Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | VTRS |
|---|---|---|
| Share price | $36.05 | $17.44 |
| Market cap | $22.17B | $20.03B |
| 1-day change | -1.64% | -0.29% |
| YTD return | +18.99% | +40.48% |
| 1-year return | +12.29% | +72.49% |
| 5-year return | -17.51% | +29.94% |
| P/E ratio (TTM) | 28.39 | — |
| Forward P/E | 23.64 | 6.52 |
| EPS (TTM) | $1.27 | $-0.36 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $3.72B | $14.30B |
| Revenue growth (YoY) | +19.19% | -2.98% |
| Net income (latest FY) | $963.00M | $-3.51B |
| Gross margin | 93.60% | 35.06% |
| Operating margin | 28.63% | -18.62% |
| Net margin | 25.89% | -24.58% |
| 52-week high | $40.17 | $18.43 |
| 52-week low | $23.62 | $9.69 |
| Distance from 52-week high | -10.26% | -5.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +19.89% | +12.96% |
| Average volume | 2.80M | 9.18M |
| Shares outstanding | 614.90M | 1.15B |
| Employees | 3,119 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed GMAB by 60.2 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.75% vs 0.00%).
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs -2.98%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
GMAB vs VTRS FAQ
Which is bigger, Genmab A/S or Viatris?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.17B compared with $20.03B for Viatris (VTRS).
Which stock has performed better over the past year, GMAB or VTRS?
VTRS returned +72.49% over the past 12 months, compared with +12.29% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Genmab A/S or Viatris?
Viatris pays a dividend yielding 2.75%, while Genmab A/S does not currently pay a regular dividend.
Are Genmab A/S and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.